Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial / image credit eking University People’s Hospital
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial

October 28th 2025

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

October 27th 2025

Semaglutide Cardioprotective Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential  / image credit John Deanfield, CBE  Courtesy of University College London
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential

October 23rd 2025

Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research
Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research

October 21st 2025

Oral Semaglutide Wins FDA Approval to Reduce Risk of MACE in Adults with T2D at High Risk
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

October 20th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.